Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.39 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.39 |
| ▸ | DUSP5 | Q16690 | 4/20 | 0.85 |
| ▸ | DUSP6 | Q16828 | 1/20 | 0.85 |
| ▸ | ING2 | Q9H160 | 3/20 | 0.78 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416771 | 0.92 | DUSP5 (1.00) | DUSP5DUSP6ING2PTPN1PLCG1 | |
| SCHEMBL29776588 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL29486957 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL15397119 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL15397115 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL29486958 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL29664959 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| SCHEMBL19203101 | 0.88 | ING2 (1.00) | DUSP5DUSP6ING2CA1CA2 | |
| Water SCHEMBL31084794 | 0.86 | ING2 (0.95) | DUSP5DUSP6ING2CA1CA2 | |
| Water SCHEMBL30366794 | 0.86 | ING2 (0.95) | DUSP5DUSP6ING2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102309-A1 | SELECTIVE RADIOTRACERS AND METHODS OF USE | LUTROO IMAGING, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250352676-A1 | N-Cyclopropyl-1-(4-(4-(Fluoro-18f)Phenyl)Pyrimidin-5-Yl)-N-Methylpiperidine- 4-Carboxamide and Uses in PET Imaging | UNIV EMORY (US) | 2025-11-20 | — | — | US | disclosed |
| US-20230225988-A1 | ANTIVIRAL USE OF CALIXARENES | CEBINA GmbH (AT) | 2023-07-20 | — | — | US | disclosed |
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | UNIV EMORY (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4167983-A1 | ANTIVIRAL USE OF CALIXARENES | CEBINA GmbH (AT) | 2023-04-26 | — | — | EP | disclosed |
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | UNIV EMORY (US) | 2022-09-29 | — | — | US | disclosed |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | EMORY UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | SLC16A8, S100A8, FGF23 | CA1 18/4885CA2 79/4885CA12 23/4885 |
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | AFF1, METTL3, VHL | CA1 38/4885CA2 571/4885CA12 149/4885 |
| US-20230225988-A1 | ANTIVIRAL USE OF CALIXARENES | CALU, CANX, CTSA | CA1 1768/4885CA2 1329/4885CA12 928/4885 |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | SLC16A8, S100A8, FGF23 | CA1 18/4885CA2 79/4885CA12 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.